Six years ago, none of the five Brown University researchers with a major new grant from the ALS Finding a Cure Foundation had even worked on amyotrophic lateral sclerosis. That’s exactly why the team has a unique approach for making much-needed progress against the untreatable neurodegenerative disease.
Dr. Anne S. De Groot is the founder, immune engineer, chief scientific officer and CEO of Providence-based vaccine company EpiVax, which champions the "vaccines-on-demand" movement. She talks with Providence Business News about her experience as a panelist at a health care conference, "The Immunology Revolution: Here Now or Hurry Up and Wait?"
Medical-device companies, under pressure from hospitals and health insurers to keep expenses down, are capitalizing on strong cash flows and the stumbling stock market to beef up cost-controlling technologies that may be critical to maintaining growth.
One in 68 children in the United States has been diagnosed with autism spectrum disorder, according to the Centers for Disease Control and Prevention. Of those, about 25 percent are never able to talk.
Xinyuan “Shawn” Chen, assistant professor of biomedical and pharmaceutical sciences at the University of Rhode Island’s College of Pharmacy, is developing a nicotine vaccine to block the drug’s entry into a smoker’s brain.